IP Library Granted Patent US 12,709,595
Granted Patent B2
US 12,709,595 · App. 18/346,315 · Granted Aug 18, 2026

Synthetic pathway to belzutifan

Inventors: Daniel A. DiRocco (Califon, NJ); Jackson Kenai Blender Cahn (Westfield, NJ); Wai Ling Cheung-Lee (Westfield, NJ); Stephanie W. Chun (Scotch Plains, NJ); J. Caleb Hethcox (New York, NY); Heather Claire Johnson (Jamaica Plain, MA); Jungchul Kim (Basking Ridge, NJ); Joshua N. Kolev (Califon, NJ); Birgit Kosjek (Westfield, NJ); Diane Le (Rahway, NJ); Scott D. McCann (Middlesex, NJ); John McIntosh (Brookline, MA); Jonathan P. McMullen (Scotch Plains, NJ); Jeffrey C. Moore (Westfield, NJ); William Morris (Randolph, NJ); Juan Esteban Velasquez Velez (Jersey City, NJ); Matthew S. Winston (Maplewood, NJ); Victoria Zhang (Bardonia, NY); Yong-Li Zhong (Edison, NJ)
Assignee: Merck Sharp & Dohme LLC
C07C317/14C07C315/04C12N9/0006C12P11/00C12Y101/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,595
App. No.
18/346,315
Filed
Jul 3, 2023
Granted
Aug 18, 2026
Kind
B2
Art Unit
1657
USPC
435/130
Abstract

The disclosure provides a novel process and synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of certain VHL-related indications and cancer.

Claims (38)

1 . A process for preparing belzutifan

comprising:

(a) contacting hydroxy indanone (5)

with a fluorinating agent under acidic conditions to yield fluoro hydroxyindanone (6),

(b) contacting the fluoro hydroxyindanone (6) with a ketoreductase comprising the full-length sequence of SEQ ID NO:2 to provide fluorodiol (7),

(c) isolating the fluorodiol (7), and

(d) converting fluorodiol (7) to belzutifan.

2 . The process of claim 1 , wherein step (b) further comprises contacting the fluoro hydroxyindanone (6) with NADP.

3 . The process of claim 1 , wherein the process further comprises preparing the hydroxy indanone (5) of step (a) by contacting indanone (4)

with FoPip4H enzyme comprising the full-length sequence of SEQ ID NO:1 and a co-substrate to provide hydroxy indanone (5).

4 . The process of claim 3 , wherein the co-substrate is α-ketoglutarate.

5 . The process of claim 3 , wherein the process further comprises preparing the indanone (4) by contacting bromo indanone (3)

with a metabisulfite salt in the presence of a Ni 2+ catalyst and a methylating agent to provide the indanone (4).

6 . The process of claim 5 , wherein the Ni 2+ catalyst is NiCl 2 -dppe.

7 . The process of claim 5 , wherein the methylating agent is selected from the group consisting of trimethyl phosphate, dimethylsulfate, methyl iodide, methyl bromide, methyl chloride, dimethyl carbonate, methyl trifluoromethane sulfonate, and trimethyloxonium tetrafluoroborate.

8 . The process of claim 5 , wherein the metabisulfite salt is an alkali metal metabisulfite salt.

9 . The process of claim 5 , wherein the process further comprises preparing the bromo indanone (3) by cyclizing phenylpropionic acid (2)

in thionyl chloride in the presence of a Lewis acid to provide the indanone (3).

10 . The process of claim 9 , wherein phenylpropionic acid (2) is prepared by reacting benzaldehyde (1)

with Meldrum's acid to provide phenylpropionic acid (2).

11 . The process of claim 1 , wherein step (d) comprises: treating fluorodiol (7) with a deoxyfluorinating agent and a base to provide trifluoro indanol (8)

and

converting trifluoro indanol (8) to belzutifan.

12 . The process of claim 11 , wherein step (d) further comprises coupling trifluoro indanol (8) with phenol (9)

to provide belzutifan.

13 . The process of claim 12 , wherein the coupling is conducted in an aqueous solution in the presence of a base.

14 . The process of claim 12 , wherein step (d) further comprises:

treating belzutifan with activated carbon;

recrystallizing decolorized belzutifan from a mixture of a dipolar aprotic solvent and water;

and isolating purified belzutifan.

15 . A process for preparing fluorodiol (7)

comprising:

(a) contacting hydroxyindanone (5)

with a fluorinating agent under acidic conditions to yield fluoro hydroxyindanone (6),

(b) contacting the fluoro hydroxyindanone (6) with a ketoreductase comprising the full-length sequence of SEQ ID NO:2 to provide fluorodiol (7); and

(c) isolating the fluorodiol (7).

16 . The process of claim 15 , wherein step (b) further comprises contacting the fluoro hydroxyindanone (6) with NADP.

17 . The process of claim 16 , wherein step (b) further comprises contacting the NADP and the fluoro hydroxyindanone (6) with a secondary alcohol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2023
From: CAHN, JACKSON KENAI BLENDER; CHUN, STEPHANIE W.; DIROCCO, DANIEL A.; HETHCOX, J. CALEB; KIM, JUNGCHUL; KOLEV, JOSHUA N.; KOSJEK, BIRGIT; MCCANN, SCOTT D.; MCMULLEN, JONATHAN P.; MOORE, JEFFREY C.; MORRIS, WILLIAM; VELASQUEZ VELEZ, JUAN ESTEBAN; WINSTON, MATTHEW S.; ZHANG, VICTORIA; CHEUNG-LEE, WAI LING; JOHNSON, HEATHER CLAIRE; LE, DIANE; MCINTOSH, JOHN; ZHONG, YONG-LI
To: MERCK SHARP & DOHME LLC
Reel/Frame 064193/0894 →
Continuity (2)
Provisional Application 63359334 · Jul 8, 2022
Related Publication 20240010613A1 · Jan 11, 2024
References Cited (22)
US 9896418B2 · Dixon et al. · 2018 [cited by applicant]
US 9908845B2 · Dixon et al. · 2018 [cited by applicant]
US 9969689B2 · Dixon et al. · 2018 [cited by applicant]
US 10144711B2 · Dixon et al. · 2018 [cited by applicant]
US 10596366B2 · Sama · 2020 [cited by applicant]
US 20220388974A1 · Dalby et al. · 2022 [cited by applicant]
Kita et al. Applied and Environmental Microbiology 65.12 (1999): 5207-5211. (Year: 1999). [cited by examiner]
Kamitori, Shigehiro, et al. “X-ray structures of NADPH-dependent carbonyl reductase from Sporobolomyces salmonicolor provide insights into stereoselective reductions of carbonyl compounds.” Journal of molecular biology … [cited by examiner]
Zhu, Dunming, et al. “Stereoselective ketone reduction by a carbonyl reductase from Sporobolomyces salmonicolor. Substrate specificity, enantioselectivity and enzyme-substrate docking studies.” Organic & Biomolecular Ch… [cited by examiner]
Kavanagh, K. L., et al. “Medium-and short-chain dehydrogenase/reductase gene and protein families: the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes.” Cellular … [cited by examiner]
Li, Hongmei, et al. “Enantioselective reduction of diaryl ketones catalyzed by a carbonyl reductase from Sporobolomyces salmonicolor and its mutant enzymes.” Advanced Synthesis & Catalysis 351.4 (2009): 583-588. (Year: … [cited by examiner]
Nguyen, Phung-Hoang, et al. “Enantioselectivity and Enzyme-Substrate Docking Studies of a Ketoreductase from Sporobolomyces salmonicolor (SSCR) and [cited by examiner]
Hibi, Makoto, et al. “Novel enzyme family found in filamentous fungi catalyzing trans-4-hydroxylation of L-pipecolic acid.” Applied and Environmental Microbiology 82.7 (2016): 2070-2077. (Year: 2016). [cited by examiner]
Graeff, Maike, et al. “The short-chain dehydrogenase/reductase engineering database (SDRED): a classification and analysis system for a highly diverse enzyme family.” Proteins: Structure, Function, and Bioinformatics 87… [cited by examiner]
NCBI; https://blast.ncbi.nlm.nih.gov/Blast.cgi; accessed Oct. 30, 2025 (Year: 2025). [cited by examiner]
NCBI2; https://blast.ncbi.nlm.nih.gov/Blast.cgi; accessed Nov. 13, 2025 (Year: 2025). [cited by examiner]
CD Search; https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi; accessed Nov. 12, 2025 (Year: 2025). [cited by examiner]
Clustal Omega; https://www.ebi.ac.uk/jdispatcher/msa/clustalo/summary?jobId=clustalo-120251112-195449-0132-8166911-p1m; accessed Nov. 12, 2025 (Year: 2025). [cited by examiner]
PDB 1YP; https://www.rcsb.org/structure/1Y1P; accessed Nov. 17, 2025 (Year: 2005). [cited by examiner]
PDB 1UM; https://www.rcsb.org/structure/1UJM; accessed Nov. 17, 2025 (Year: 2004). [cited by examiner]
Wehn, Paul M. et al., Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-… [cited by applicant]
Ku, Rui et al., 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma, J… [cited by applicant]